USE OF STEROIDAL GLYCOSIDES, PHARMACEUTICAL FORMULATIONS, USE OF FURCRAEA FOETIDA PLANT EXTRACTS, PROCESS FOR PRODUCING FURCRAEA FOETIDA PLANT EXTRACTS AND METHOD FOR TREATING SKIN DISORDERS

Abstract

The present invention relates, in its broadest aspects, to steroidal glycosides useful in the treatment of skin disorders. Particularly, the invention relates to the use of certain steroidal glucosides, per se, or in the form aglycona, derivatives of spirostanol, of its precursor furastanol, or mixtures thereof, used in the treatment of skin disorders, for instance, psoriasis. The invention further relates to formulations containing steroidal glycosides, the process of obtaining extract from the Furcraea foetida plant, and a method of treating skin disorders.

Claims

1-15. (canceled)

16. An extract from the Furcraea foetida plant comprising steroidal glycosides of the Z-A type, wherein A is a spirostanol type structure represented by Formula I ##STR00005## or a furostanol type structure represented by Formula II, ##STR00006## wherein: R is H, H or O; and Z is H or one or more saccharide groups having 1 to 12 rings.

17. The extract of claim 16, wherein A has a spacial structure represented by Formula III ##STR00007##

18. The extract of claim 16, wherein Z is one or more saccharide groups having 6 rings.

19. The extract of claim 16, wherein the one or more saccharide groups is selected from the group consisting of: glucose, rhamnose, galactose, fucose, mannose, fructose, ribose, xylose, arabinose, and glucuronide.

20. The extract of claim 16, wherein the steroidal glycosides are selected from the group consisting of: (24S,25S)-24-[(-beta-D-glucopyranosyl)oxy]-5 alpha-furoan-3 beta-yl-beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta-D-glucopyranosyl-(1.fwdarw.2)-O-[O-alpha-L-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1.fwdarw.3)]-O-beta-D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranoside; (23S,25R)-6 alpha-[(Beta-D-glucopyranosyl) oxy]-23-hydroxy-5 alpha-spirostan-3 beta-D-fucoidan; (25R)-26-[(beta-D-glucopyranosyl)) oxy]-6 alpha-hydroxy-22 alpha-methoxy-5 alpha-furoan-3 beta-yl-O-beta-D-glucopyranosyl-(1.fwdarw.3)-O-Beta-D-glucopyranosyl-(1.fwdarw.2)-O-[O-alpha-l-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1.fwdarw.3)]-O-beta-D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranoside; (25R)-5 alpha-spirostan-3 beta-Yl-O-Beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta-D-glucopyranosyl-(1.fwdarw.2)-O-[O-alpha-1-rhamnopyranosyl-(1.fwdarw.4)-beta-D-Glucopyranosyl-(1.fwdarw.3)]-O-beta-D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranoside; (25R)-6 alpha-hydroxy-5 alpha-spirostan-3 beta-yl O-Beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta-D-glucopyranosyl-(1.fwdarw.2)-O-[O-alpha-1-rhamnopyranosyl-(1.fwdarw.4)-beta-D-Glucopyranosyl-(1.fwdarw.3)]-O-beta-D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranoside; (25R)-3 beta-[(O-beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta-D-glucopyranosyl-(1.fwdarw.2)-O[O-alpha-L-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1.fwdarw.3)]-O-beta-D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranoside)oxy]-5 alpha-spirostan-12-one (furcreastatin); (23S,25R)-3 beta, 23-dihydroxy-5 alpha-spirostan-6 alpha-yl-Beta-D-glucopyranoside; (25R)-5 alpha-spirostane-3 beta, 6a-di-1-bis-beta-beta-D-glucopyranoside; (23S,25R)-23-hydroxy-5 alpha-spirostane-3 beta, 6a-di-yl bis-Beta-D-glucopyranoside; (25R)-26-[(beta-D-glucopyranosyl) oxy]-22 alpha-methoxy-5 alpha-furoan-3 beta-yl-O-beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta-D-glucopyranosyl-(1.fwdarw.2)-O-[O-alpha-1-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1.fwdarw.3)]-O-beta-D-Glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranoside; (25R)-3 beta-[(O-beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta-D-glucopyranosyl-(1.fwdarw.2)-O-[O-Alpha-l-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1.fwdarw.3)]-O-beta-D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranosyl) oxy]-26 a-[(beta-D-glucopyranosyl) oxy]-22-methoxy-5 a-furoan-12-one; (25R)-22 alpha-methoxy-5 alpha-furoan-3 beta, 6α, 26-triyl tris-beta-D-glucopyranoside; and combinations thereof.

21. The extract of claim 16, wherein Z is a hexasaccharide represented by Formula IV ##STR00008##

22. The extract of claim 16, wherein the steroidal glycoside is (25R)-6 Alpha-hydroxy-5 Alpha-espirostan-3 beta-yl O-beta-D-glucopyranosyl-(1.fwdarw.3)-O-beta-D-glucopyranosyl-(1.fwdarw.2)-O[O-Alpha-L-rhamnopyranosyl-(1.fwdarw.4)-beta-D-glucopyranosyl-(1.fwdarw.3)]-O-beta-D-glucopyranosyl-(1.fwdarw.4)-beta-D-galactopyranosyl.

23. A pharmaceutical composition comprising the extract of claim 16 and a pharmaceutically accepted carrier.

24. A method of treating skin disorders, comprising administering an effective amount of the extract of claim 16 to a subject, wherein the skin disorder is one of acne, rosacea, psoriasis, skin vesicles, sun burns, physical or chemical burns, dermatitis, eczema, skin rash, allergic reactions, fungal, bacterial and viral infections, pruritis, cellulite, urticaria, chapped lips, tattoos, waxed areas, diabetic ulcers, radiation dermatitis, scleroderma, erisipela, ichthyosis, decubitus ulcers, and cracked feet and hands.

Description

EXAMPLE 1—PROCESS FOR OBTAINING THE EXTRACT

[0045] 30 parts in weight of ethanol and 70 parts in weight of Furcraea foetida leaves pulp, previously crushed, are blended in and left in contact together for a certain amount of time, for instance, until 48 hours. It is followed by filtration.

EXAMPLE 2—FORMULATION AND TREATMENT

[0046] The liquid of example 1 is formulated as a lotion, which is applied, periodically upon skin areas affected by psoriasis. After a few applications, it can be observed that the disease regression, both visually and concerning the pruritus, occurs in a fast and effective way.

[0047] A person skilled in the art will be able to, from the information and examples provided herein, perform the invention in equivalent forms, not expressly disclosed, however, with the same, or substantially the same function, and the same, or substantially the same results, even though they are under the protective scope of the attached set of claims.